Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
NCT07746453Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of Universal STAR-T Cell Injection in IgA nephropathy (IgAN) and primary membranous nephropathy (PMN), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Adverse Events at 104 weeks, Dose-Limiting Toxicities at 28 days and 2 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Universal STAR-T Cell Injection
03
Conditions
IgA nephropathy (IgAN)primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07746453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746453.